![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JG Chung, GN Levy and WW Weber
Department of Pharmacology, University of Michigan, Ann Arbor 48109- 0626.
The distribution of N-acetyltransferase (NAT) activity in 35 tissues of inbred rapid acetylator C57BL/6J and slow acetylator congenic B6.A-NatS mice was determined by incubation of tissue cytosols with 2- aminofluorene or p-aminobenzoic acid followed by HPLC assay. Tissues examined included the gastrointestinal tract, lymphoid tissues, skin, blood components, and other major organs. NAT activity was found in all tissues examined except blood plasma and seminal vesicles. Peyer's patches had the highest activity with either substrate, and lymphoid tissue, in general, was high in NAT activity as was skin and much of the digestive system. The acetylator polymorphism was apparent in most tissues for both p-aminobenzoic acid and 2-aminofluorene. The difference between rapid and slow acetylator phenotypes was usually greater with p-aminobenzoic acid than with 2-aminofluorene. The presence of NAT in the 33 tissues of rapid and slow acetylator mice, as well as the absence of NAT in plasma and seminal vesicles, was confirmed by immunoblots using an anti-NAT antibody raised in rabbits. These results indicate the widespread distribution of NAT activity and the relative abundance of extrahepatic N-acetylation capacity in the mouse.
This article has been cited by other articles:
|
|
 |
|
  D. W. Hein, J. Bendaly, J. R. Neale, and M. A. Doll Systemic Functional Expression of N-Acetyltransferase Polymorphism in the F344 Nat2 Congenic Rat Drug Metab. Dispos., December 1, 2008; 36(12): 2452 - 2459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Loehle, V. Cornish, L. Wakefield, M. A. Doll, J. R. Neale, Y. Zang, E. Sim, and D. W. Hein N-Acetyltransferase (Nat) 1 and 2 Expression in Nat2 Knockout Mice J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 724 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wakefield, V. Cornish, F. Broackes-Carter, and E. Sim Arylamine N-acetyltransferase 2 Expression in the Developing Heart J. Histochem. Cytochem., May 1, 2005; 53(5): 583 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Sugamori, S. Wong, A. Gaedigk, V. Yu, H. Abramovici, R. Rozmahel, and D. M. Grant Generation and Functional Characterization of Arylamine N-Acetyltransferase Nat1/Nat2Double-Knockout Mice Mol. Pharmacol., July 1, 2003; 64(1): 170 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Hein, M. A. Doll, A. J. Fretland, M. A. Leff, S. J. Webb, G. H. Xiao, U.-S. Devanaboyina, N. A. Nangju, and Y. Feng Molecular Genetics and Epidemiology of the NAT1 and NAT2 Acetylation Polymorphisms Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 29 - 42. [Abstract] [Full Text]
|
|
|
|
|
|
L. Estrada-Rodgers, G. N. Levy, and W. W. Weber Substrate Selectivity of Mouse N-Acetyltransferases 1, 2, and 3 Expressed in COS-1 Cells Drug Metab. Dispos., May 1, 1998; 26(5): 502 - 505. [Abstract] [Full Text]
|
|
|
|
 |
|
 D Hickman, J Pope, S D Patil, G Fakis, V Smelt, L A Stanley, M Payton, J D Unadkat, and E Sim Expression of arylamine N-acetyltransferase in human intestine Gut, March 1, 1998; 42(3): 402 - 409. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
